H. Lundbeck Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de H. Lundbeck de 10.5% y 3.8% por año respectivamente. Se prevé que el BPA crezca en un 10.6% al año. Se espera que la rentabilidad financiera sea de 12.6% en 3 años.

Información clave

10.5%

Tasa de crecimiento de los beneficios

10.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	18.2%
Tasa de crecimiento de los ingresos	3.8%
Rentabilidad financiera futura	12.6%
Cobertura de analistas	Good
Última actualización	04 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

BATS-CHIXE:HLUNBC - Estimaciones futuras de los analistas y datos financieros pasados (DKK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	24,293	4,078	5,414	5,752	9
12/31/2025	22,984	3,601	4,865	5,262	10
12/31/2024	21,788	3,043	4,437	4,341	10
6/30/2024	20,671	2,586	4,128	4,609	N/A
3/31/2024	20,239	2,298	4,245	4,791	N/A
12/31/2023	19,912	2,290	3,579	4,080	N/A
9/30/2023	19,614	2,467	3,528	4,426	N/A
6/30/2023	19,381	2,479	3,523	4,457	N/A
3/31/2023	18,918	2,384	3,292	4,102	N/A
12/31/2022	18,246	1,916	2,699	3,519	N/A
9/30/2022	17,619	1,603	2,051	2,615	N/A
6/30/2022	16,913	1,236	1,744	2,313	N/A
3/31/2022	16,398	1,109	1,344	1,959	N/A
12/31/2021	16,299	1,318	1,660	2,272	N/A
9/30/2021	16,521	1,873	2,405	2,949	N/A
6/30/2021	16,971	1,965	2,379	2,912	N/A
3/31/2021	17,381	2,110	3,263	3,757	N/A
12/31/2020	17,672	1,581	3,359	3,837	N/A
9/30/2020	17,818	904	2,713	3,171	N/A
6/30/2020	17,490	1,242	2,910	3,354	N/A
3/31/2020	17,366	1,507	1,502	1,960	N/A
12/31/2019	17,036	2,313	2,165	2,609	N/A
9/30/2019	16,811	3,091	3,210	3,621	N/A
6/30/2019	17,309	3,395	2,736	3,462	N/A
3/31/2019	17,766	3,606	4,100	4,815	N/A
12/31/2018	18,117	3,907	5,277	5,981	N/A
9/30/2018	18,313	3,806	5,057	5,922	N/A
6/30/2018	18,028	3,627	5,368	6,197	N/A
3/31/2018	17,608	3,236	N/A	5,397	N/A
12/31/2017	17,234	2,624	N/A	4,045	N/A
9/30/2017	17,007	2,544	N/A	3,731	N/A
6/30/2017	16,607	1,988	N/A	3,551	N/A
3/31/2017	16,075	1,612	N/A	3,420	N/A
12/31/2016	15,634	1,211	N/A	3,126	N/A
9/30/2016	15,202	290	N/A	4,158	N/A
6/30/2016	14,923	-1,289	N/A	2,755	N/A
3/31/2016	14,801	-5,427	N/A	936	N/A
12/31/2015	14,594	-5,694	N/A	197	N/A
9/30/2015	14,108	-5,879	N/A	-1,330	N/A
6/30/2015	13,625	-4,615	N/A	-464	N/A
3/31/2015	13,444	-565	N/A	1,379	N/A
12/31/2014	13,468	-153	N/A	1,610	N/A
9/30/2014	13,808	503	N/A	2,601	N/A
6/30/2014	14,181	765	N/A	2,095	N/A
3/31/2014	14,269	119	N/A	2,982	N/A
12/31/2013	15,258	855	N/A	3,760	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (10.5% al año) de HLUNBC es superior a la tasa de ahorro (1.9%).

Beneficios vs. Mercado: Se prevé que los beneficios (10.5% al año) de HLUNBC crezcan menos que el mercado UK (14.4% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de HLUNBC crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (3.8% al año) de HLUNBC crezcan más rápidamente que los del mercado UK (3.6% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 3.8% al año) de HLUNBC crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de HLUNBC sea baja dentro de 3 años (12.6%).

H. Lundbeck Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

Recent updates

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Less than half of directors are independent

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento